Literature DB >> 24114721

Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis.

Pilar Sandoval1, Jose Antonio Jiménez-Heffernan, Ángela Rynne-Vidal, María Luisa Pérez-Lozano, Álvaro Gilsanz, Vicente Ruiz-Carpio, Raquel Reyes, Julio García-Bordas, Konstantinos Stamatakis, Javier Dotor, Pedro L Majano, Manuel Fresno, Carlos Cabañas, Manuel López-Cabrera.   

Abstract

Peritoneal dissemination is a frequent metastatic route for cancers of the ovary and gastrointestinal tract. Tumour cells metastasize by attaching to and invading through the mesothelial cell (MC) monolayer that lines the peritoneal cavity. Metastases are influenced by carcinoma-associated fibroblasts (CAFs), a cell population that derives from different sources. Hence, we investigated whether MCs, through mesothelial-mesenchymal transition (MMT), were a source of CAFs during peritoneal carcinomatosis and whether MMT affected the adhesion and invasion of tumour cells. Biopsies from patients with peritoneal dissemination revealed the presence of myofibroblasts expressing mesothelial markers in the proximity of carcinoma implants. Prominent new vessel formation was observed in the peritoneal areas harbouring tumour cells when compared with tumour-free regions. The use of a mouse model of peritoneal dissemination confirmed the myofibroblast conversion of MCs and the increase in angiogenesis at places of tumour implants. Treatment of omentum MCs with conditioned media from carcinoma cell cultures resulted in phenotype changes reminiscent of MMT. Adhesion experiments demonstrated that MMT enhanced the binding of cancer cells to MCs in a β1-integrin-dependent manner. Scanning electron microscopy imaging showed that the enhanced adhesion was mostly due to increased cell-cell interaction and not to a mere matrix exposure. Invasion assays suggested a reciprocal stimulation of the invasive capacity of tumour cells and MCs. Our results demonstrate that CAFs can derive from mesothelial cells during peritoneal metastasis. We suggest that MMT renders the peritoneum more receptive for tumour cell attachment/invasion and contributes to secondary tumour growth by promoting its vascularization.
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  carcinoma-associated fibroblasts; mesothelial cells; mesothelial-to-mesenchymal transition; peritoneal metastasis

Mesh:

Substances:

Year:  2013        PMID: 24114721     DOI: 10.1002/path.4281

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  63 in total

1.  Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis.

Authors:  Hilary A Kenny; Madhu Lal-Nag; Min Shen; Betul Kara; Dominik A Nahotko; Kristen Wroblewski; Sarah Fazal; Siquan Chen; Chun-Yi Chiang; Yen-Ju Chen; Kyle R Brimacombe; Juan Marugan; Marc Ferrer; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2019-09-27       Impact factor: 6.261

Review 2.  Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review.

Authors:  Juliette O A M van Baal; Cornelis J F van Noorden; Rienk Nieuwland; Koen K Van de Vijver; Auguste Sturk; Willemien J van Driel; Gemma G Kenter; Christianne A R Lok
Journal:  J Histochem Cytochem       Date:  2017-11-22       Impact factor: 2.479

3.  Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.

Authors:  Peter C Hart; Hilary A Kenny; Niklas Grassl; Karen M Watters; Lacey M Litchfield; Fabian Coscia; Ivana Blaženović; Lisa Ploetzky; Oliver Fiehn; Matthias Mann; Ernst Lengyel; Iris L Romero
Journal:  Cell Rep       Date:  2019-12-17       Impact factor: 9.423

4.  EPAS1 promotes peritoneal carcinomatosis of non-small-cell lung cancer by enhancing mesothelial-mesenchymal transition.

Authors:  Qiang Zhen; Yaxiao Zhang; Lina Gao; Renfeng Wang; Weiwei Chu; Xiaojian Zhao; Zhe Li; Huixian Li; Bing Zhang; Baolei Lv; Jiabao Liu
Journal:  Strahlenther Onkol       Date:  2020-07-17       Impact factor: 3.621

5.  Lung cancer cells induce senescence and apoptosis of pleural mesothelial cells via transforming growth factor-beta1.

Authors:  Zhi-Feng Miao; Wen-Ya Li; Zhen-Ning Wang; Ting-Ting Zhao; Ying-Ying Xu; Yong-Xi Song; Jin-Yu Huang; Hui-Mian Xu
Journal:  Tumour Biol       Date:  2014-11-30

6.  Macrophage-mediated transfer of cancer-derived components to stromal cells contributes to establishment of a pro-tumor microenvironment.

Authors:  Michinobu Umakoshi; So Takahashi; Go Itoh; Sei Kuriyama; Yuto Sasaki; Kazuyoshi Yanagihara; Masakazu Yashiro; Daichi Maeda; Akiteru Goto; Masamitsu Tanaka
Journal:  Oncogene       Date:  2018-11-20       Impact factor: 9.867

Review 7.  Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics.

Authors:  Elly De Vlieghere; Laurine Verset; Pieter Demetter; Marc Bracke; Olivier De Wever
Journal:  Virchows Arch       Date:  2015-08-11       Impact factor: 4.064

8.  Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis.

Authors:  R Satoyoshi; N Aiba; K Yanagihara; M Yashiro; M Tanaka
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

9.  Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Authors:  Hilary A Kenny; Chun-Yi Chiang; Erin A White; Elizabeth M Schryver; Mohammed Habis; Iris L Romero; Andras Ladanyi; Carla V Penicka; Joshy George; Karl Matlin; Anthony Montag; Kristen Wroblewski; S Diane Yamada; Andrew P Mazar; David Bowtell; Ernst Lengyel
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

Review 10.  Comprehensive Roles and Future Perspectives of Exosomes in Peritoneal Metastasis of Gastric Cancer.

Authors:  Xiangliu Chen; Haiyong Wang; Yingying Huang; Yanyan Chen; Chuanzhi Chen; Wei Zhuo; Lisong Teng
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.